GSK’s Phase III trial of breast cancer combination treatment fails to meet primary endpoint
The trial failed to meet the primary endpoint of improved disease free survival (DFS) compared to single agent therapy with trastuzumab. The company said that the safety profile
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.